#GLP-1 class

Coverage of the GLP-1 receptor agonist family and its successors.

A UK model compared sleeve gastroplasty, sleeve gastrectomy and a gastric balloon with semaglutide over five years.

FLOW established kidney-outcome evidence for semaglutide in diabetic CKD. A translational review explains why SGLT2 combination trials are next.

A Canadian analysis estimated how far GLP-1 receptor agonist prices would need to fall to become cost-effective.

A 2026 meta-analysis linked GLP-1 therapies to changes in selected inflammation and metabolic biomarkers in type 2 diabetes.

A phase 2 trial found no significant fibrosis benefit from adding zalfermin to semaglutide across F2 to compensated F4 MASH.

A preclinical rat study tested a thermosensitive semaglutide hydrogel. It cannot establish human efficacy, dosing, or safety.

A laboratory study found different semaglutide effects across patient-derived PPGL cultures, including a signal in three RET-linked tumors.

An indirect comparison favoured semaglutide on one MASH endpoint but cannot replace a randomized head-to-head trial.

A mouse and cell study linked tirzepatide with less liver fat and inflammation, with Dectin-1 signaling proposed as part of the mechanism.

A 2026 South Korean cohort linked semaglutide and liraglutide initiation with selected safety outcomes, without proving causation.

A Lancet letter raises the maintenance question. SURMOUNT-MAINTAIN supports continued tirzepatide but does not supply an individual dosing formula.

A 25-year semaglutide model weighed cost per QALY against projected equity for older adults with obesity and cardiovascular disease.